Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. - McDermott DF; Sosman JA; Sznol M; Massard C; Gordon MS; Hamid O; Powderly JD; Infante JR; Fassò M; Wang YV; Zou W; Hegde PS; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016)